Cart
sales@molnova.com
NPS2390
CAS No. 226878-01-9
NPS2390( —— )
Catalog No. M21958 CAS No. 226878-01-9
NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 44 | In Stock |
|
| 5MG | 33 | In Stock |
|
| 10MG | 55 | In Stock |
|
| 25MG | 107 | In Stock |
|
| 50MG | 183 | In Stock |
|
| 100MG | 300 | In Stock |
|
| 200MG | 414 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNPS2390
-
NoteResearch use only, not for human use.
-
Brief DescriptionNPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively).
-
DescriptionNPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively). Treatment of NPS2390 was conducive to inhibit the proliferation and reverse phenotypic modulation of PASMCs by regulating autophagy levels.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptormGluR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number226878-01-9
-
Formula Weight307.4
-
Molecular FormulaC19H21N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 6.25 mg/mL (20.33 mM)
-
SMILESO=C(NC12CC3CC(CC(C3)C1)C2)c1cnc2ccccc2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Peng X , Wei C , Li H Z , et al. NPS2390, a Selective Calcium-sensing Receptor Antagonist Controls the Phenotypic Modulation of Hypoxic Human Pulmonary Arterial Smooth Muscle Cells by Regulating Autophagy[J]. Journal of Translational Internal Medicine, 2019, 7(2):59-68.
molnova catalog
related products
-
cis-PDA
cis-PDA is a general ionotropic receptor antagonist. cis-PDA acts by blocking NMDA, AMPA, and kainate-mediated responses.
-
KM02894
KM02894 is a glutamate release inhibitor. Cancer cells release high levels of glutamate that can disrupt normal bone turnover, which can lead to cancer-induced bone pain.KM02894 may be used in the study of tumor-related diseases.
-
FITM
FITM is a potent negative allosteric modulator of mGlu1 receptor(Ki : 2.5 nM).
